ÃÀ¸ß÷
ÓªÒµ×Éѯ
Öйú£º
Email: marketing@medicilon.com.cn
ÓªÒµ×ÉѯרÏߣº400-780-8018
£¨½öÏÞЧÀÍ×Éѯ£¬£¬£¬£¬£¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©
´¨É³×ܲ¿µç»°: +86 (21) 5859-1500
ÍâÑó£º
+1(781)535-1428(U.S.)
0044 7790 816 954 (Europe)
Email:marketing@medicilon.com



Ò½ÏßÒ©ÎÅ1. 3ÔÂ27ÈÕ£¬£¬£¬£¬£¬NMPA¹ÙÍøÐû²¼£¬£¬£¬£¬£¬Åú×¼Çà·åÒ½Ò©ÏÂÊô×Ó¹«Ë¾½Î÷¿Æî£Ò©ÒµÉ걨µÄ1ÀàÁ¢ÒìÒ©ÂêÊæÀɳΤƬÉÏÊУ¬£¬£¬£¬£¬¸ÃÒ©ÊÊÓÃÓÚ¼ÈÍù¿µ½¡µÄ12Ëê¼°ÒÔÉÏÇàÉÙÄêºÍ³ÉÈË´¿´âÐÔ¼×ÐͺÍÒÒÐÍÁ÷¸Ð»¼ÕßµÄÖÎÁÆ£¬£¬£¬£¬£¬²»°üÀ¨±£´æÁ÷¸ÐÏà¹Ø²¢·¢Ö¢¸ßΣº¦µÄ»¼Õß¡£¡£¡£
2. ¿ËÈÕ£¬£¬£¬£¬£¬ÕÄÖÝÆ¬×Ðñ¥Ò©Òµ¹É·ÝÓÐÏÞ¹«Ë¾»ñµÃ¹ú¼ÒÒ©Æ·¼àÊÓ¹ÜÀí¾ÖÅú׼ǩ·¢µÄÑø³²¿ÅÁ£¡¶Ò©ÎïÁÙ´²ÊÔÑéÅú׼֪ͨÊé¡·£¬£¬£¬£¬£¬ÔÞ±¾Ç®Æ·¿ªÕ¹ÁÙ´²ÊÔÑé¡£¡£¡£¸Ã²úÆ·ÊÇ»ùÓÚÔºÄÚÖÆ¼Á¿ª·¢µÄÖÐÒ©1.1ÀàÁ¢ÒìÒ©£¬£¬£¬£¬£¬ÄâÓÃÓÚÖÎÁÆÂѳ²´¢±¸¹¦Ð§¼õÍË¡£¡£¡£
3. 3ÔÂ27ÈÕ£¬£¬£¬£¬£¬¿µÔµÒ©Òµ£¨600557£©Ðû²¼Í¨¸æ£¬£¬£¬£¬£¬¿ËÈÕÊÕµ½¹ú¼ÒÒ©Æ·¼àÊÓ¹ÜÀí¾ÖÇ©·¢µÄÁ¬²Î¸üÄê¿ÅÁ£¡¶Ò©ÎïÁÙ´²ÊÔÑéÅú׼֪ͨÊé¡·¡£¡£¡£¸ÃҩƷ˳Ӧ֢Ϊ¸üÄêÆÚ×ÛºÏÕ÷£¨ÒõÐé»ðÍúÖ¤£©£¬£¬£¬£¬£¬ÊôÓÚÖÐÒ©Á¢ÒìÒ© 1.1À࣬£¬£¬£¬£¬¼ÁÐÍΪ¿ÅÁ£¼Á¡£¡£¡£
4. 3ÔÂ26ÈÕ£¬£¬£¬£¬£¬¾ýʵÉúÎïÐû²¼£¬£¬£¬£¬£¬¸Ã¹«Ë¾×ÔÖ÷Ñз¢µÄ¿¹PD-1µ¥¿¹Ò©ÎïÌØÈðÆÕÀûµ¥¿¹£¨ÐÂ¼ÓÆÂÉÌÆ·Ãû£ºLOQTORZI£©ÁªºÏ˳²¬ºÍ¼ªÎ÷Ëû±õÓÃÓÚ¸´·¢¡¢²»¿ÉÊÖÊõ»ò·ÅÁƵ쬣¬£¬£¬£¬»ò×ªÒÆÐÔ±ÇÑʰ©³ÉÈË»¼ÕßµÄÒ»ÏßÖÎÁƵÄÉÏÊÐÔÊÐíÉêÇë»ñµÃÐÂ¼ÓÆÂÎÀÉú¿ÆÑ§¾Ö£¨HSA£©Åú×¼¡£¡£¡£
3ÔÂ27ÈÕ£¬£¬£¬£¬£¬Î÷ÁëÔ´Ò©ÒµÓëÑǺçÒ½Ò©Ðû¹«¸æ¿¢Éî¶ÈÕ½ÂÔÏàÖú¡£¡£¡£Ë«·½½«ÒÔ¼×»ÇËá°¬Á¢²¼ÁÖ×¢ÉäÒº£¨ÒÔϼò³Æ¡°°¬Á¢²¼ÁÖ¡±£©ÎªÏàÖú»ù´¡£¬£¬£¬£¬£¬ÅäºÏÍÆ½ø¿¹Ö×ÁöÒ©ÎïµÄÑз¢ÓëÉÌÒµ»¯Àú³Ì¡£¡£¡£×÷ΪÏàÖúÖØµã£¬£¬£¬£¬£¬Î÷ÁëÔ´Ò©ÒµÒÑ»ñµÃ°¬Á¢²¼ÁÖÖйúÉú²úÅú¼þ£¬£¬£¬£¬£¬²¢ÊÚÓèÑǺçÒ½Ò©ÔÚÖйúÊг¡¶À¼ÒÉÌÒµ»¯È¨Òæ¡£¡£¡£
1. ¿ËÈÕ£¬£¬£¬£¬£¬ÖÐɽ´óѧ´ÞöÁÍŶÓÔÚNature Cancer£¨IF=23.5£©ÔÚÏß½ÒÏþÌâΪ¡°Palmitoylation of GPX4 via the targetable ZDHHC8 determines ferroptosis sensitivity and antitumor immunity¡±µÄÑо¿ÂÛÎÄ£¬£¬£¬£¬£¬¸ÃÑо¿Õ¹ÏÖÁËS-רéµõ£»£»£»£»£»¯Í¨¹ý¹Èë׸ÊëĹýÑõ»¯Îïø4 (GPX4)µ÷ÀíÌúéæÃüµÄÒªº¦×÷Óᣡ£¡£
Zhou, L., Lian, G., Zhou, T. et al. Palmitoylation of GPX4 via the targetable ZDHHC8 determines ferroptosis sensitivity and antitumor immunity. Nat Cancer (2025). https://doi.org/10.1038/s43018-025-00937-y
Ïà¹ØÐÂÎÅ